Literature DB >> 20806431

Chemoprotective effects of curcumin in esophageal epithelial cells exposed to bile acids.

Matthew R Bower1, Harini S Aiyer, Yan Li, Robert C G Martin.   

Abstract

AIM: To investigate the ability of curcumin to counteract the impact of bile acids on gene expression of esophageal epithelial cells.
METHODS: An esophageal epithelial cell line (HET-1A) was treated with curcumin in the presence of deoxycholic acid. Cell proliferation and viability assays were used to establish an appropriate dose range for curcumin. The combined and individual effects of curcumin and bile acid on cyclooxygenase-2 (COX-2) and superoxide dismutase (SOD-1 and SOD-2) gene expression were also assessed.
RESULTS: Curcumin in a dose range of 10-100 micromol/L displayed minimal inhibition of HET-1A cell viability. Deoxycholic acid at a concentration of 200 micromol/L caused a 2.4-fold increase in COX-2 gene expression compared to vehicle control. The increased expression of COX-2 induced by deoxycholic acid was partially reversed by the addition of curcumin, and curcumin reduced COX-2 expression 3.3- to 1.3-fold. HET-1A cells exposed to bile acid yielded reduced expression of SOD-1 and SOD-2 genes with the exception that high dose deoxycholic acid at 200 mumol/L led to a 3-fold increase in SOD-2 expression. The addition of curcumin treatment partially reversed the bile acid-induced reduction in SOD-1 expression at all concentrations of curcumin tested.
CONCLUSION: Curcumin reverses bile acid suppression of gene expression of SOD-1. Curcumin is also able to inhibit bile acid induction of COX-2 gene expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20806431      PMCID: PMC2932918          DOI: 10.3748/wjg.v16.i33.4152

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  41 in total

1.  Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells.

Authors:  G D Stoner; M E Kaighn; R R Reddel; J H Resau; D Bowman; Z Naito; N Matsukura; M You; A J Galati; C C Harris
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

2.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

Authors:  A L Cheng; C H Hsu; J K Lin; M M Hsu; Y F Ho; T S Shen; J Y Ko; J T Lin; B R Lin; W Ming-Shiang; H S Yu; S H Jee; G S Chen; T M Chen; C A Chen; M K Lai; Y S Pu; M H Pan; Y J Wang; C C Tsai; C Y Hsieh
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

Review 3.  Anticancer potential of curcumin: preclinical and clinical studies.

Authors:  Bharat B Aggarwal; Anushree Kumar; Alok C Bharti
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

4.  Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.

Authors:  Navtej S Buttar; Kenneth K Wang; Olga Leontovich; Jay Y Westcott; Rodney J Pacifico; Marlys A Anderson; Krishnawatie K Krishnadath; Lori S Lutzke; Lawrence J Burgart
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex.

Authors:  S M Plummer; K A Holloway; M M Manson; R J Munks; A Kaptein; S Farrow; L Howells
Journal:  Oncogene       Date:  1999-10-28       Impact factor: 9.867

7.  Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.

Authors:  Ricky A Sharma; Stephanie A Euden; Sharon L Platton; Darren N Cooke; Aisha Shafayat; Heather R Hewitt; Timothy H Marczylo; Bruno Morgan; David Hemingway; Simon M Plummer; Munir Pirmohamed; Andreas J Gescher; William P Steward
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

8.  Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent.

Authors:  Baljeet S Kaur; George Triadafilopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-08       Impact factor: 4.052

9.  Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.

Authors:  Marc Bardou; Alan N Barkun; Joumana Ghosn; Marie Hudson; Elham Rahme
Journal:  Clin Gastroenterol Hepatol       Date:  2004-10       Impact factor: 11.382

10.  Oxidative stress has a role in malignant transformation in Barrett's oesophagus.

Authors:  Eero I T Sihvo; Jukka T Salminen; Tuomo K Rantanen; O Juhani Rämö; Markku Ahotupa; Martti Färkkilä; Merja I Auvinen; Jarmo A Salo
Journal:  Int J Cancer       Date:  2002-12-20       Impact factor: 7.396

View more
  4 in total

1.  Effect on pro-inflammatory and antioxidant genes and bioavailable distribution of whole turmeric vs curcumin: Similar root but different effects.

Authors:  Robert C G Martin; Harini S Aiyer; Daniel Malik; Yan Li
Journal:  Food Chem Toxicol       Date:  2011-11-04       Impact factor: 6.023

Review 2.  Curcumin: reclaiming the lost ground against cancer resistance.

Authors:  Siraj Shaikh; Javed Shaikh; Yusufi Sadia Naba; Kailas Doke; Khursheed Ahmed; Mujahid Yusufi
Journal:  Cancer Drug Resist       Date:  2021-06-19

Review 3.  Molecular mechanisms of chemopreventive phytochemicals against gastroenterological cancer development.

Authors:  Min-Yu Chung; Tae Gyu Lim; Ki Won Lee
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

4.  Hepatic protection and anticancer activity of curcuma: a potential chemopreventive strategy against hepatocellular carcinoma.

Authors:  Yan Li; Xue Shi; Jingwen Zhang; Xiang Zhang; Robert C G Martin
Journal:  Int J Oncol       Date:  2013-11-21       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.